US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Propanc Biopharma, Inc.

0.2779

-0.1121-28.74%

Post-market: 0.2505-0.0274-9.86%19:59 EST

Volume:1.90M

Turnover:563.42K

Market Cap:3.71M

PE:-0.06

High:0.3495

Open:0.3401

Low:0.2570

Close:0.3900

52wk High:11.00

52wk Low:0.0002

Shares:13.36M

Float Shares:3.40M

Volume Ratio:1.55

T/O Rate:55.93%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.9510

EPS(LYR):-14.8490

ROE:-1236.83%

ROA:-427.27%

PB:0.26

PE(LYR):-0.02

Loading ...

Overview Company News Filings

Press Release: Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline

Press Release: Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

BRIEF-Propanc Biopharma Announces Strategic Financing Agreement Of Up To $100 Million With Hexstone Capital

Propanc Biopharma Inc - Preferred Stock Convertible Into Common Stock at $5.00 per Share

THOMSON REUTERS

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million With Hexstone Capital

THOMSON REUTERS

Propanc Biopharma Inc. Announces Series C Preferred Stock Purchase Agreement with Hexstone Capital

Propanc Biopharma Reports No Revenue for Fiscal Year Ended June 30, 2025

Propanc Biopharma receives certificate of grant from USPTO

BRIEF-Propanc Biopharma Announces Plan To Acquire $100 Million Of Ethereum

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

THOMSON REUTERS

Propanc Biopharma Inc. Successfully Lists on Nasdaq Capital Market, Raises $4 Million in Public Offering

BRIEF-Propanc Biopharma Provides Shareholder Update

Propanc Biopharma Inc. Uplists to Nasdaq, Launches $4 Million Public Offering

Propanc Biopharma Announces Closing of Public Offering and Uplisting to Nasdaq

THOMSON REUTERS

Top Midday Gainers

MT Newswires Live

Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August

Propanc Biopharma Shares Advance Following Nasdaq Debut

MT Newswires Live

Top Premarket Gainers

MT Newswires Live

BRIEF-Propanc Biopharma Announces Nasdaq Uplisting And Pricing Of $4 Million Public Offering

Propanc Biopharma Inc - Prices Public Offering of 1,000,000 Shares at $4.00 Each

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PPCB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PPCB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","market":"US","secType":"STK","nameCN":"Propanc Biopharma, Inc.","latestPrice":0.2779,"timestamp":1769720400000,"preClose":0.39,"halted":0,"volume":1904289,"hourTrading":{"tag":"盘后","latestPrice":0.2505,"preClose":0.2779,"latestTime":"19:59 EST","volume":123190,"amount":31755.5139,"timestamp":1769734795667,"change":-0.0274,"changeRate":-0.098597,"amplitude":0.116589},"delay":0,"changeRate":-0.28743589743589754,"floatShares":3404500,"shares":13364244,"eps":-4.951,"marketStatus":"Not Yet Opened","change":-0.1121,"latestTime":"01-29 16:00:00 EST","open":0.3401,"high":0.3495,"low":0.257,"amount":563416.6544208,"amplitude":0.237179,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-4.951,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1769763600000},"marketStatusCode":0,"adr":0,"listingDate":1743998400000,"exchange":"NASDAQ","adjPreClose":0.39,"preHourTrading":{"tag":"盘前","latestPrice":0.3489,"preClose":0.39,"latestTime":"09:29 EST","volume":68711,"amount":24573.277775069997,"timestamp":1769696984994,"change":-0.0411,"changeRate":-0.105385,"amplitude":0.163333},"postHourTrading":{"tag":"盘后","latestPrice":0.2505,"preClose":0.2779,"latestTime":"19:59 EST","volume":123190,"amount":31755.5139,"timestamp":1769734795667,"change":-0.0274,"changeRate":-0.098597,"amplitude":0.116589},"volumeRatio":1.549502},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","floatShares":3404500,"roa":"-427.27%","roe":"-1236.83%","lyrEps":-14.848963,"volumeRatio":1.549502,"shares":13364244,"dividePrice":0,"high":0.3495,"amplitude":0.237179,"preClose":0.39,"low":0.257,"week52Low":0.0002,"pbRate":"0.26","week52High":11,"institutionHeld":0,"latestPrice":0.2779,"eps":-4.951,"divideRate":0,"volume":1904289,"delay":0,"ttmEps":-4.951,"open":0.3401,"prevYearClose":0.536601,"prevWeekClose":0.28,"prevMonthClose":0.5366,"prevQuarterClose":0.5366,"fiveDayClose":0.266,"twentyDayClose":0.58,"sixtyDayClose":1.24},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PPCB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-01-29","symbol":"PPCB","defaultRemindTime":1738161000000,"type":"split","dateTimestamp":1738126800000,"forFactor":60000,"toFactor":1,"ratio":60000},{"market":"US","date":"2023-05-23","symbol":"PPCB","defaultRemindTime":1684848600000,"type":"split","dateTimestamp":1684814400000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2020-11-19","symbol":"PPCB","defaultRemindTime":1605796200000,"type":"split","dateTimestamp":1605762000000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2019-06-24","symbol":"PPCB","type":"split","dateTimestamp":1561348800000,"forFactor":500,"toFactor":1,"ratio":500}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PPCB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PPCB\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PPCB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PPCB","date":"2026-01-28","current":-0.05613,"percent":0.931034,"low":-1.336323,"twenty":-0.450277,"median":-0.230387,"eighty":-0.123469,"high":-0.048332,"avg":-0.307582,"sd":0.228511,"marketCap":3971853},"quantilePoints":[{"date":"2025-04-04","current":-0.050633,"twenty":-0.050633,"median":-0.050633,"eighty":-0.050633,"marketCap":84546},{"date":"2025-04-07","current":-0.048332,"twenty":-0.050633,"median":-0.050633,"eighty":-0.049713,"marketCap":80703},{"date":"2025-08-22","current":-0.938461,"twenty":-0.969897,"median":-0.655598,"eighty":-0.050633,"marketCap":51812834},{"date":"2025-08-29","current":-0.721182,"twenty":-0.884372,"median":-0.710781,"eighty":-0.050633,"marketCap":39816759},{"date":"2025-09-05","current":-0.457673,"twenty":-0.820575,"median":-0.688821,"eighty":-0.213449,"marketCap":25268328},{"date":"2025-09-12","current":-0.457673,"twenty":-0.778969,"median":-0.631034,"eighty":-0.41283,"marketCap":25268328},{"date":"2025-09-19","current":-0.506214,"twenty":-0.755854,"median":-0.517772,"eighty":-0.439644,"marketCap":27948302},{"date":"2025-09-26","current":-0.418378,"twenty":-0.712861,"median":-0.510837,"eighty":-0.435021,"marketCap":23098825},{"date":"2025-10-03","current":-0.399917,"twenty":-0.699454,"median":-0.498124,"eighty":-0.407301,"marketCap":23564414},{"date":"2025-10-10","current":-0.408611,"twenty":-0.69067,"median":-0.457673,"eighty":-0.403395,"marketCap":24076684},{"date":"2025-10-17","current":-0.343407,"twenty":-0.669984,"median":-0.449583,"eighty":-0.385572,"marketCap":20234660},{"date":"2025-10-24","current":-0.321672,"twenty":-0.645772,"median":-0.432247,"eighty":-0.369488,"marketCap":18953985},{"date":"2025-10-31","current":-0.269509,"twenty":-0.610693,"median":-0.4245,"eighty":-0.343407,"marketCap":15880366},{"date":"2025-11-07","current":-0.241906,"twenty":-0.556142,"median":-0.418378,"eighty":-0.313847,"marketCap":14253909},{"date":"2025-11-14","current":-0.169965,"twenty":-0.518234,"median":-0.404264,"eighty":-0.269509,"marketCap":10014876},{"date":"2025-11-21","current":-0.174454,"twenty":-0.514536,"median":-0.397743,"eighty":-0.234995,"marketCap":11061584},{"date":"2025-11-28","current":-0.188344,"twenty":-0.512687,"median":-0.384703,"eighty":-0.189884,"marketCap":11942288},{"date":"2025-12-05","current":-0.173885,"twenty":-0.509912,"median":-0.372748,"eighty":-0.182127,"marketCap":11025501},{"date":"2025-12-12","current":-0.170028,"twenty":-0.504827,"median":-0.356448,"eighty":-0.174606,"marketCap":10780935},{"date":"2025-12-19","current":-0.151754,"twenty":-0.498818,"median":-0.343407,"eighty":-0.171335,"marketCap":9622255},{"date":"2025-12-26","current":-0.139108,"twenty":-0.496968,"median":-0.326019,"eighty":-0.170682,"marketCap":8820401},{"date":"2026-01-02","current":-0.113099,"twenty":-0.476627,"median":-0.315152,"eighty":-0.168873,"marketCap":7171266},{"date":"2026-01-09","current":-0.101254,"twenty":-0.460447,"median":-0.284723,"eighty":-0.163023,"marketCap":6420182},{"date":"2026-01-16","current":-0.074044,"twenty":-0.457673,"median":-0.262988,"eighty":-0.151375,"marketCap":4694858},{"date":"2026-01-23","current":-0.056065,"twenty":-0.453513,"median":-0.243754,"eighty":-0.138341,"marketCap":3554888},{"date":"2026-01-28","current":-0.062641,"twenty":-0.450277,"median":-0.230387,"eighty":-0.123469,"marketCap":3971853}],"updateTime":1769750369308},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PPCB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2582874193","title":"Press Release: Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2582874193","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582874193?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:45","pubTimestamp":1762782300,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, Nov. 10, 2025  -- Propanc Biopharma, Inc.  , a biopharmaceutical company developing new treatments for patients suffering from recurrent and metastatic cancer, today announced that it has entered into a securities purchase agreement with Hexstone Capital LLC , a family office that has invested in a significant number of Digital Asset Treasury  companies across a range of digital assets including BTC, ETH, SOL, DOGE, ATH, OG, and INJ. The agreement is for a private placement of up to $100 Million in convertible preferred stock and will be deployed to support its digital asset acquisition strategy and accelerate the Company's R&D pipeline, focusing on PRP entering a First-In-Human study second half of 2026. Upon closing, the Company received an initial investment of $1 million based on the issue of 100 shares of newly designated Series C Convertible Preferred Stock, each with a par value of $0.01 and an initial stated value of $10,000.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAQC","BK4139","PPCB","DAT","DAAQU"],"gpt_icon":0},{"id":"2580735931","title":"Press Release: Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2580735931","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580735931?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:00","pubTimestamp":1762257600,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, Nov. 04, 2025  -- Propanc Biopharma, Inc.  , a biopharmaceutical company developing new treatments for patients suffering from recurrent and metastatic cancer, today announced a strategic initiative to pursue the acquisition of Digital Asset Treasury  companies that are currently trading below their Market Cap to Net Asset Value .The Company's management believes that acquiring undervalued DAT entities presents a compelling opportunity to strengthen Propanc's balance sheet, diversify its asset base, and create long-term shareholder value. These DAT companies typically hold substantial reserves of leading digital assets such as Bitcoin  and Ethereum  on their balance sheets.\"We see this as a strategic diversification initiative that can unlock value for Propanc shareholders,\" said James Nathanielsz, CEO of Propanc Biopharma. \"By identifying DAT companies trading below their intrinsic value, we aim to leverage our public company platform to build a diversified digit","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["METHmain","US12M.BOND","US10Y.BOND","US2Y.BOND","US7Y.BOND","US5Y.BOND","ETH","BK4139","BTC","BTC.USD.CC","ETH.USD.HKCC","TLTW","TMF","BK4601","PPCB","DAT","US3Y.BOND","US6M.BOND","US30Y.BOND","ETH.USD.CC","BTC.USD.HKCC","ETHU"],"gpt_icon":1},{"id":"2575782011","title":"BRIEF-Propanc Biopharma Announces Strategic Financing Agreement Of Up To $100 Million With Hexstone Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2575782011","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575782011?lang=en_us&edition=fundamental","pubTime":"2025-10-15 20:46","pubTimestamp":1760532419,"startTime":"0","endTime":"0","summary":"BRIEF-Propanc Biopharma Announces Strategic Financing Agreement Of Up To $100 Million With Hexstone CapitalOct 15 (Reuters) - Propanc Biopharma Inc PPCB.O:PROPANC BIOPHARMA ANNOUNCES STRATEGIC FINANCI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nTUABPC5VT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"gpt_icon":0},{"id":"2575820657","title":"Propanc Biopharma Inc - Preferred Stock Convertible Into Common Stock at $5.00 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2575820657","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575820657?lang=en_us&edition=fundamental","pubTime":"2025-10-15 20:45","pubTimestamp":1760532300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nTUABPC5VT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"gpt_icon":0},{"id":"2575782743","title":"Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million With Hexstone Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2575782743","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575782743?lang=en_us&edition=fundamental","pubTime":"2025-10-15 20:45","pubTimestamp":1760532300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nTUABPC5VT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"gpt_icon":0},{"id":"2575240054","title":"Propanc Biopharma Inc. Announces Series C Preferred Stock Purchase Agreement with Hexstone Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2575240054","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575240054?lang=en_us&edition=fundamental","pubTime":"2025-10-15 05:25","pubTimestamp":1760477158,"startTime":"0","endTime":"0","summary":"Propanc Biopharma Inc. has entered into a Securities Purchase Agreement with Hexstone Capital LLC for a private placement of Series C Preferred Stock. The agreement includes the issuance of 100 shares of Series C Preferred Stock and a warrant to purchase up to 9,900 additional shares, with conversion terms linked to the company's common stock trading price. Completion of the deal is subject to certain closing conditions, including the filing of a Certificate of Designation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL27Cf4N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"gpt_icon":0},{"id":"2571365826","title":"Propanc Biopharma Reports No Revenue for Fiscal Year Ended June 30, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2571365826","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571365826?lang=en_us&edition=fundamental","pubTime":"2025-09-30 05:30","pubTimestamp":1759181454,"startTime":"0","endTime":"0","summary":"Propanc Biopharma Inc. released its financial results for the fiscal year ended June 30, 2025. The company reported no revenue for the years ended June 30, 2025 and 2024, as it is still in the development stage and has not yet generated sales from its product candidates. Propanc Biopharma's lead product candidate, PRP, continues to be developed as a potential treatment for pancreatic, ovarian, and colorectal cancer. The company stated that it is focused on raising additional capital to sustain its operations and advance its business plan. No updates on net income or profit/loss were provided in the disclosed information. The company emphasized its ongoing efforts in research and development and highlighted the need for further funding to support its activities.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL94V8gD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"gpt_icon":0},{"id":"2568991364","title":"Propanc Biopharma receives certificate of grant from USPTO","url":"https://stock-news.laohu8.com/highlight/detail?id=2568991364","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568991364?lang=en_us&edition=fundamental","pubTime":"2025-09-17 20:50","pubTimestamp":1758113428,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced that a certificate of grant for the Company’s “proenzyme composition” patent was received from the US Patent & T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-receives-certificate-of-grant-from-uspto-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-receives-certificate-of-grant-from-uspto-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PPCB","BK4139"],"gpt_icon":0},{"id":"2564381216","title":"BRIEF-Propanc Biopharma Announces Plan To Acquire $100 Million Of Ethereum","url":"https://stock-news.laohu8.com/highlight/detail?id=2564381216","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564381216?lang=en_us&edition=fundamental","pubTime":"2025-09-03 00:55","pubTimestamp":1756832128,"startTime":"0","endTime":"0","summary":"BRIEF-Propanc Biopharma Announces Plan To Acquire $100 Million Of EthereumPropanc Biopharma Inc PPCB.O:PROPANC BIOPHARMA ANNOUNCES PLAN TO ACQUIRE $100 MILLION OF ETHEREUMSource text: ID:nGNX2LMGk3Further company coverage: PPCB.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nTUA9SCCMD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"gpt_icon":0},{"id":"2564800391","title":"Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum","url":"https://stock-news.laohu8.com/highlight/detail?id=2564800391","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564800391?lang=en_us&edition=fundamental","pubTime":"2025-09-02 21:00","pubTimestamp":1756818000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nTUA9SCCMD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"gpt_icon":0},{"id":"2563906475","title":"Propanc Biopharma Inc. Successfully Lists on Nasdaq Capital Market, Raises $4 Million in Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2563906475","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563906475?lang=en_us&edition=fundamental","pubTime":"2025-08-29 06:00","pubTimestamp":1756418416,"startTime":"0","endTime":"0","summary":"Propanc Biopharma Inc. , a biopharmaceutical company focused on developing novel cancer treatments, has successfully closed an underwritten public offering of 1,000,000 shares of its common stock at a price of $4.00 per share. The shares commenced trading on the Nasdaq Capital Market on August 15, 2025, under the ticker symbol \"PPCB.\" The company raised aggregate gross proceeds of $4,000,000 from the offering. D. Boral Capital LLC and Craft Capital Management LLC served as the book running managers for this offering.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on August 28, 2025, and is solely responsible for the information c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nNDL2dXXFc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"gpt_icon":0},{"id":"2562124474","title":"BRIEF-Propanc Biopharma Provides Shareholder Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2562124474","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562124474?lang=en_us&edition=fundamental","pubTime":"2025-08-25 20:59","pubTimestamp":1756126795,"startTime":"0","endTime":"0","summary":"BRIEF-Propanc Biopharma Provides Shareholder UpdateAug 25 (Reuters) - Propanc Biopharma Inc PPCB.O:PROPANC BIOPHARMA PROVIDES SHAREHOLDER UPDATESource text: ID:nGNX4fF43wFurther company coverage: PPCB.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nTUA9R6JXJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"gpt_icon":0},{"id":"2560110326","title":"Propanc Biopharma Inc. Uplists to Nasdaq, Launches $4 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2560110326","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560110326?lang=en_us&edition=fundamental","pubTime":"2025-08-20 05:25","pubTimestamp":1755638736,"startTime":"0","endTime":"0","summary":"Propanc Biopharma Inc., a biopharmaceutical company focused on developing cancer treatments, announced the pricing of an underwritten public offering of 1,000,000 shares of its common stock at $4.00 per share. The offering, expected to generate approximately $4 million in gross proceeds, coincides with the company's approval to list its common stock on the Nasdaq Capital Market under the symbol \"PPCB.\" Trading is set to commence on August 15, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 19, 2025, and is ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nNDL7PGCxk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"gpt_icon":0},{"id":"2560199216","title":"Propanc Biopharma Announces Closing of Public Offering and Uplisting to Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2560199216","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560199216?lang=en_us&edition=fundamental","pubTime":"2025-08-19 20:30","pubTimestamp":1755606602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nTUA3B5GZD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"gpt_icon":0},{"id":"2560182419","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2560182419","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560182419?lang=en_us&edition=fundamental","pubTime":"2025-08-19 01:24","pubTimestamp":1755537882,"startTime":"0","endTime":"0","summary":"Soligenix  said Monday that the US Food and Drug Administration has granted orphan drug designation to dusquetide for the treatment of Behcet's disease, an inflammatory disorder of the blood vessels.Shares surged 85% as intraday trading volume catapulted to more than 146.2 million from a daily average of about 8 million.Propanc Biopharma  shares soared 131% in heavy trading after midday on Monday following their debut on Nasdaq on Friday.More than 63.3 million shares traded intraday.Aspire Biopharma  said Monday its investigational sublingual aspirin product demonstrated \"higher and more rapid\" mean plasma concentrations of acetylsalicylic acid, compared with standard chewed aspirin tablets.Shares jumped 52%, with intraday trading volume at over 430.7 million from a daily average of about 15 million.Price: 6.63, Change: +3.76, Percent Change: +130.84","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ASBP","BK4007","BK4139","PPCB","SNGX"],"gpt_icon":0},{"id":"2560825041","title":"Crude Oil Moves Higher; US Homebuilder Sentiment Declines In August","url":"https://stock-news.laohu8.com/highlight/detail?id=2560825041","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560825041?lang=en_us&edition=fundamental","pubTime":"2025-08-19 01:15","pubTimestamp":1755537313,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/08/47191981/crude-oil-moves-higher-us-homebuilder-sentiment-declines-in-august","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SQQQ","BK4091","QID","BK4139","EMPD","RSKD","TQQQ","QLD","NVIW.SI","BK4583","GDRX","USAW.SI","BK4023","NQmain","BK4539","PSQ","USJW.SI",".IXIC","TSYW.SI","MNQmain","PPCB","BK4007","BK4167","ASBP"],"gpt_icon":1},{"id":"2560186264","title":"Propanc Biopharma Shares Advance Following Nasdaq Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2560186264","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560186264?lang=en_us&edition=fundamental","pubTime":"2025-08-18 22:52","pubTimestamp":1755528771,"startTime":"0","endTime":"0","summary":"Propanc Biopharma  shares jumped more than 146% in recent Monday trading following their debut on Nasdaq on Friday.Intraday trading volume was more than 48 million shares.The company said last week it expects to close on Monday its initial public offering of 1 million shares.Price: 7.08, Change: +4.21, Percent Change: +146.52","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4112","NQmain","LU2095319765.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4139","LU2210150020.SGD",".IXIC","IE00BKPKM429.USD","NDAQ","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2210149790.SGD","BK4588","BK4585","PPCB"],"gpt_icon":0},{"id":"2560987904","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2560987904","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560987904?lang=en_us&edition=fundamental","pubTime":"2025-08-18 19:38","pubTimestamp":1755517103,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) shares were more than 151% higher pre-bell Monday, reversing from a 28% drop in the previous session.BioXcel Therapeutics (BTAI) stock was up 29% after the company said it rec","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2517655028.SGD","LU2517655374.HKD","BK4588","LU2517655291.USD","BTAI","DAY","BK4130","BK4585","XNET","BK4139","BK4023","PPCB"],"gpt_icon":1},{"id":"2559996089","title":"BRIEF-Propanc Biopharma Announces Nasdaq Uplisting And Pricing Of $4 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2559996089","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559996089?lang=en_us&edition=fundamental","pubTime":"2025-08-15 11:01","pubTimestamp":1755226897,"startTime":"0","endTime":"0","summary":"BRIEF-Propanc Biopharma Announces Nasdaq Uplisting And Pricing Of $4 Million Public OfferingAug 14 (Reuters) - Propanc Biopharma Inc PPCB.PK:PROPANC BIOPHARMA ANNOUNCES NASDAQ UPLISTING AND PRICING OF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250815:nTUABNMGPL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"gpt_icon":0},{"id":"2559999676","title":"Propanc Biopharma Inc - Prices Public Offering of 1,000,000 Shares at $4.00 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2559999676","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559999676?lang=en_us&edition=fundamental","pubTime":"2025-08-15 11:00","pubTimestamp":1755226800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250815:nTUABNMGPL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":43,"code":"91000000","status":"200"}]}}